Big Pharma spends more on marketing than R&D
Mike Dobson | 04.01.2008 10:36 | Globalisation | Health | Other Press | World
[P]romotion consumes 24.4% of the sales dollar versus 13.4% for R&D. In light of these numbers, one can safely argue that marketing is predominant over R&D in the pharmaceutical industry, contrary to the industry’s claim.
Citation: Gagnon MA, Lexchin J (2008) The Cost of Pushing Pills: A New Estimate of Pharmaceutical Promotion Expenditures in the United States. PLoS Med 5(1): e1 doi:10.1371/journal.pmed.0050001
![](/img/extlink.gif)
Mike Dobson
e-mail:
michael.dob871@onetel.net